Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Firm is enrolling patients in IDE-approved Dermagraft diabetic foot ulcer clinical trial in compliance with recommendation of FDA's General and Plastic Surgery Devices Panel, which voted to approve the company's PMA application on the condition that additional studies be completed ("The Gray Sheet" Feb. 2, p. 6). If initial trials including180 patients at up to 30 sites show that healing rates are equivalent to earlier pivotal trials, the firm can terminate the study and will have sufficient data to support its PMA application within a year. The trial will continue until 330 patient have been enrolled if such results are not obtained. Separately, Dermagraft-TC will be sold as TransCyte effective Oct. 1
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.